Stock has rallied approximately 2.7% since earnings to trade near $27.40 and is up over 9% year-to-date, showing persistent buying momentum in the $26–$28 area.

Revenues slipped 1.2% year-on-year to $17.56 B in the latest quarter yet beat forecasts by 5.5%, while EPS is projected at $0.77, down 16.3%. A $62.6 B organic revenue base, two-year margin improvements of 17.8 ppt and a 6.3%-6.5% dividend yield underscore internal financial strength. Execution in the pipeline—20 pivotal trial starts in 2026, >70% efficacy in a Lyme vaccine and positive TALAPRO-3 results—bolsters management’s targets of $59.6 B revenue and $12.8 B earnings by 2028 and $10 B in oncology revenue by 2030.

US regulators face scrutiny for delayed public warnings on an ischemic stroke safety signal after the Pfizer bivalent booster, even as Pfizer works to satisfy statistical efficacy thresholds for its experimental Lyme vaccine in global filings. Pharmaceutical pricing power and revenue face headwinds from looming pricing negotiations and patent expirations, while a competitive landscape led by Pfizer, Johnson & Johnson, Merck, and others must navigate regulatory and exclusivity risks amid a projected $112.4 billion oncology market by 2030.

Early Lyme vaccine efficacy and pipeline wins in oncology and immunology have reignited investor enthusiasm around a post-COVID growth reboot, fueling bargain-hunting on under-valued shares and upbeat buy ratings, even as missed primary endpoints and looming U.S. drug-pricing talks temper optimism with regulatory and policy caution.